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CCR5 Usage by CCL5 Induces a Selective Leukocyte
Recruitment in Human Skin Xenografts In Vivo
Patricia de Nadaı¨1,7, Ce´cile Chenivesse1,7, Jules Gilet1, Henri Porte2, Han Vorng1, Ying Chang1,3,
Andrew F. Walls4, Benoıˆt Wallaert1,5, Andre´-Bernard Tonnel1,5, Anne Tsicopoulos1,5 and
Hans-Gu¨nter Zerwes6
CCR5 is one of the major inflammatory chemokine receptors with potential therapeutical applications in
humans. However, the redundancy of chemokines and their receptors, and the species specificity of chemokine
receptor antagonists pose challenges to understanding of the role they play in pharmacological situations. To
address this question, we used a humanized severe combined immunodeficient mouse model grafted with
human skin and autologous leukocytes, and evaluated the effect of a blocking antibody against human CCR5,
on CCL5-induced cutaneous leukocyte recruitment in vivo. At baseline, CCL5 induced a significant recruitment
of T cells mainly of the memory phenotype, of monocytes/macrophages, eosinophils, and IFN-gþ but not IL-4þ
and IL-5þ cells. In vivo, anti-CCR5 antibody was able to almost completely inhibit the recruitment of monocytes/
macrophages and T-helper (Th)1-type cells to inhibit partially the attraction of memory T cells, but had no effect
on eosinophil infiltration, although all these cell types express other CCL5 binding chemokine receptors than
CCR5. These results indicate that the in vivo environment regulates target cell specificity of CCL5 leading to
differential cell recruitment, suggesting that antagonizing CCR5 receptor may be of therapeutic value in
diseases such as acquired immuno deficiency syndrome, where CCL5/CCR5, monocytes, and Th1-type cells play
a predominant role.
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INTRODUCTION
The recruitment of effector cells is an important step in the
development of an inflammatory response and is orchestrated
in part by chemokines, which act through specialized surface
receptors. The preferential cell accumulation in tissue
suggests that there are specific pathways used for their
accumulation in vivo. Understanding these mechanisms
could aid in developing pharmacological therapies that
would block their recruitment. The chemokine regulated on
activation, normal T cells expressed and secreted or CCL5 in
the new nomenclature mediates the trafficking and homing of
T cells and monocytes but also of basophils, eosinophils,
natural killer cells, dendritic cells (DCs), and mast cells
(Schall, 1991) in vitro but also in vivo as we have shown in a
humanized severe combined immunodeficient (SCID) mouse
model (Fahy et al., 2001). CCL5 production which is
generated predominantly by CD8þ T cells, epithelial cells,
fibroblasts, and platelets is increased in a number of
inflammatory disorders and pathologies (Appay and Row-
land-Jones, 2001). CCL5 also plays a key role in the immune
response to viral infection. It has been reported that CCL5 can
mediate enhancement of HIV-specific T-cell cytotoxicity
(Hadida et al., 1998), and can suppress the replication of HIV
in vitro (Cocchi et al., 1995). CCL5 acts by binding to the
chemokine receptors CCR1, CCR3, and CCR5. However, the
respective role of these different receptors in mediating the
response to CCL5 is not well understood. Among them, CCR5
has been particularly studied because of its function of
coreceptor for entry of M-tropic strains of HIV into cells
(Murphy, 2001). CCR5 is a G-protein-coupled seven-trans-
membrane receptor that binds macrophage inflammatory
protein (MIP)-1a/CCL3, MIP-1b/CCL4, and CCL5. CCR5 is
expressed on Th1-type lymphocytes, monocytes/macro-
phages, basophils, eosinophils, and on DCs when they are
in the immature stage (Mueller and Strange, 2004). To
evaluate CCR5 usage by CCL5-recruited human cells in tissue
in vivo, we used a hu-SCID mouse model grafted with
autologous human full-thickness skin and peripheral blood
mononuclear cells (PBMC) (Tsicopoulos et al., 1998; Fahy
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et al., 2001). The model of SCID mice grafted with skin alone
(Juhasz et al., 1993; Yan et al., 1993; Nickoloff et al., 1995;
Christofidou-Solomidou et al., 1996, 1997b) or followed by
reconstitution with PBMC has been previously extensively
used in the field of skin diseases (Christofidou-Solomidou
et al., 1997a; Gilhar et al., 1997) and to study different types
of T-cell-mediated cutaneous inflammation (Petzelbauer
et al., 1996; Tsicopoulos et al., 1998) and graft rejection
(Murray et al., 1994; Sultan et al., 1997).
In order to determine the pattern of immune response
linked to CCR5 engagement by CCL5, the effects of a
neutralizing antibody to human CCR5 on CCL5-induced
leukocyte recruitment was investigated. We show that in
contrast to the in vitro redundancy observed with this
receptor–ligand pair, there is a fine specificity of CCR5-
mediated cell recruitment by CCL5 in vivo.
RESULTS
Neutralizing anti-CCR5 antibody inhibits CCL5-induced human
PBMC and murine eosinophil migration in vitro
To assess the potency of anti-CCR5 antibody in inhibiting
CCL5-induced cell recruitment, in vitro chemotaxis assays
were performed using human anti-CD3/anti-CD28-activated
PBMC and a human CD8 T-cell line incubated with
increasing concentrations of anti-CCR5 antibody. The isotype
control had no effect on CCL5-induced PBMC migration,
whereas anti-CCR5 antibody completely inhibited this
migration at a concentration of 3 mg/106 cells (Figure 1a).
The same effect was obtained for the CD8 T-cell line (data
not shown).
We have previously shown that in the model of skin
xenograft, there are no human eosinophils, whereas eosino-
phils of murine origin can be attracted into the graft because
they react to human chemokines (Fahy et al., 2001; Senechal
et al., 2002). Indeed, mice are reconstituted with human
PBMC devoided of human eosinophils. Therefore, the cross-
reactivity of the anti-human CCR5 antibody with murine
eosinophils was evaluated. Anti-CCR5 antibody was able to
inhibit partly the chemotaxis of murine eosinophils obtained
from IL-5 transgenic mice (anti-CCR5 57% versus control
IgG2a 4%), which clearly indicated a functional cross-
reactivity between the anti-human CCR5 antibody and the
murine CCR5 on eosinophils (Figure 1b).
CCR5 participates in CCL5-induced memory T-cell recruitment
in vivo
The use of mononuclear cells and skin specimens obtained
from the same human donor for each group of mice was of
importance in this SCID mouse model, because it avoided
any allogenicity following the reconstitution phase. More-
over, the use of two skin grafts per mouse allowed each
mouse to be its own control. Previous studies showed that the
optimal time point for CCL5-induced maximal recruitment
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Figure 1. Inhibitory effects of neutralizing anti-CCR5 antibody on human
PBMC and murine eosinophil chemotaxis in vitro. (a) Dose-dependent
inhibitory effect of CCR5-blocking antibody on human PBMC chemotaxis.
Activated human PBMC were incubated with increasing concentrations of
anti-CCR5 or IgG2a antibodies, and chemoattracted by CCL5. Results are
expressed as the percentage of inhibition of PBMC migration. (b) Functional
chemotactic cross-reactivity between anti-human CCR5 and murine
eosinophils. Eosinophils from IL-5 transgenic mice were incubated with
10mg/ml of anti-CCR5 or control IgG2a antibodies and chemoattracted using
human CCL5. Results are expressed as means7SEM number of recruited
eosinophils per field (n¼ 3).
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Figure 2. Effect of anti-CCR5 treatment on CCL5-induced skin xenograft
lymphocyte infiltration. Infiltration of human CD45þ leukocytes, CD4þ
T cells, IL-2R CD25þ T cells, and CD45ROþ memory T cells, following
CCL-5 versus diluent challenges in 26 skin grafts obtained from normal
donors, 24 hours after intravenous antibody injection and intraperitoneal
introduction of IgG2a- or anti-CCR5-treated autologous human PBMC.
Results are expressed as the number of positive cells per mm2. Median values
are represented by the solid bars. Differences within the four groups were first
evaluated by using the Kruskal–Wallis test and were found statistically
significant for the four markers. Comparisons within CCL5 and diluent values
were performed by using the Wilcoxon test. Comparisons between IgG2a and
anti-CCR5-treated groups were performed by using the Mann–Whitney U-test
after subtraction of the diluent values from CCL5 values. P-values as
indicated, NS: not significant.
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was 24 hours, and the optimal dose 4 mg, in human subjects
(Beck et al., 1997). In our hu-SCID mouse model, intradermal
injection of CCL5 induced a significant recruitment of total
CD45þ leukocytes in both the control and anti-CCR5-treated
groups, as compared to the diluent-injected site (Figure 2).
There was no difference of recruitment between the two
groups. The same pattern was observed for CD4þ T-
lymphocytes as well as for CD8þ cells (data not shown).
IL-2R CD25þ T cells were recruited by CCL5; however, there
was no statistical difference between the anti-CCR5- or
isotype-treated groups (Figure 2). For memory CD45ROþ
T cells, there was a significant recruitment after CCL5
injection in both groups; however, the absolute number
of recruited CD45ROþ cells was significantly lower in the
anti-CCR5 than in the control-treated group, showing that
anti-CCR5 treatment significantly decreased the number of
recruited memory T cells by about 67% (Figure 2).
CCR5 is the main receptor involved in CCL5-induced
monocyte/macrophage but not eosinophil recruitment in vivo
Compared with the diluent-injected skin graft, CD68þ
monocytes/macrophages were attracted by CCL-5 in the
isotype-treated group and this recruitment was strongly
inhibited following anti-CCR5 treatment (88% inhibition),
showing that CCR5 is a major pathway of monocyte/
macrophage recruitment by CCL5 (Figure 3). A microphoto-
graph of CD68þ cells after CCL5 injection into human skin
xenografts is shown in control- (Figure 5a) and anti-CCR5-
treated groups (Figure 5b). In contrast, dermal CD1aþ
immature DCs and BB1þ basophils, which have been shown
to express CCR5 in vitro, were not significantly attracted by
CCL5 in our in vivo model (Figure 3). Murine eosinophils
express CCR1, CCR3, and CCR5 (Oliveira et al., 2002), all
able to bind CCL5. In both groups of mice, murine
eosinophils were attracted by CCL5, as compared with
baseline, whether or not they received anti-CCR5 antibody,
suggesting that CCR5 is not a major pathway of eosinophil
recruitment by CCL5 in vivo (Figure 3).
CCR5 is the primary receptor involved in CCL5-induced IFN-cþ
cell recruitment in vivo
In order to evaluate whether CCR5 has a preferential role in
mediating CCL5-induced recruitment of cells characterized
by the expression of different cytokines, Th1 and Th2-type
cytokine-producing cells were assessed by immunohisto-
chemistry. CCL5 did not induce a significant recruitment of
IL-2-, IL-4-, and IL-5-positive cells compared with the diluent-
alone, whereas IFN-g þ cells were consistently attracted at
the site of the chemokine injection (Figure 4). Interestingly,
anti-CCR5 treatment strongly reduced this recruitment by
about 82% compared to the isotype control (P¼0.02). An
example of microphotograph showing IFN-gþ cells after
CCL5 injection into human skin xenografts is shown in
control- (Figure 5c) and anti-CCR5-treated groups (Figure 5d).
Thus, CCR5 is of major importance for the recruitment of
Th1-type cells in vivo.
DISCUSSION
Much is known about receptor usage by chemokines in vitro,
but the effective action of a given chemokine on its receptor
in vivo is critically dependent upon a number of environ-
mental factors. For example, glycosaminoglycans present on
cell surfaces and in the extracellular matrix are involved in
chemokine oligomerization and have a critical role in the in
vivo effect of some chemokines. CCL5 oligomerization is not
mandatory for CCR1 and CCR5 activation in vitro, although it
has been reported to be important for its in vivo chemotactic
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Figure 3. Effect of anti-CCR5 treatment on CCL5-induced skin xenograft
leukocyte infiltration. Infiltration of human CD68þ monocytes/macrophages,
CD1aþ immature DCs, BB1þ basophils, and murine MBPþ eosinophils,
following CCL-5 versus diluent challenges as described in Figure 2. Results
are expressed as in Figure 2. Kruskal–Wallis test was not significant for
CD1aþ and BB1þ cell infiltration.
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Figure 4. Effect of anti-CCR5 treatment on CCL5-induced skin xenograft
cytokine-expressing cell infiltration. Infiltration of human Th1 and Th2
cytokine-expressing cells, following CCL-5 versus diluent challenges as
described in Figure 2. Results are expressed as in Figure 2. Kruskal–Wallis test
was only significant for IFN-gþ cell infiltration.
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activity (Proudfoot et al., 2003). Moreover, the expression of
a given receptor on a cell surface does not mean that it is
functional, for example, in a particular cytokine environment,
chemokine receptors and in particular CCR5 can act as
decoys to eliminate an excess of chemokines, therefore
loosing their activation and chemoattractant capacity
(D’Amico et al., 2000). Finally, in vivo, chemokine receptors
exhibit an important plasticity which is the basis for the
dynamic migration of the cells bearing those receptors (Lloyd
et al., 2000). As more chemokine receptor antagonists appear
as potential treatments intended to be used in humans
(Proudfoot, 2002), and because of the redundancy of
chemokines and their receptors and their species specificities
(Liang et al., 2000), it is important to determine in vivo, and
in a human setting, their spectrum of action. Indeed, targeting
only one chemokine receptor might be insufficient to knock
down the recruitment of a particular subset of cells given the
expression of multiple receptors able to bind the same
chemokine. This is particularly true for CCR5, which is
coexpressed with CCR1 on monocytes/macrophages and
Th1-type cells, and with CCR3 on eosinophils and basophils,
all these receptors binding CCL5. We therefore used SCID
mice reconstituted with human PBMCs (hu-SCID mice) and
grafted with human skin to evaluate CCR5 usage by CCL5-
recruited leukocytes. In a previous study, we have used such
a model to evaluate the in vivo effect of a wide range of
chemokines, and in particular of the intradermal injection of
CCL5, which induced a cutaneous leukocyte infiltration of
human T cells, monocytes/macrophages, basophils, IL-4þ
and IFN-gþ cells, and murine eosinophils (Fahy et al., 2001).
In the present study, in the isotype-treated group, CCL5
induced a recruitment of T cells which consisted mainly of
the CD4þ subpopulation, although some CD8þ T cells were
also attracted. Among them, CD25þ (either activated or
regulatory) and CD45ROþ memory subpopulations were
particularly recruited, which is in agreement with the known
in vitro effect of CCL5 on memory T cells (Schall et al., 1990).
As compared with our previous study, more CD68þ
monocytes/macrophages and less basophils were recruited
by CCL5 in the present work. This may be linked to donor
variations, or alternately to the use of the control isotype
antibody. The recruitment of murine eosinophils to sites of
CCL5 injection is consistent with their known expression of
CCR1, CCR3, and CCR5 (Oliveira et al., 2002). We have
previously shown that murine eosinophils are attracted by
human CCR3 ligands and in particular CCL5 (Fahy et al.,
2001), which explains the cross-reactive effect observed in
the SCID model here. In terms of cells involved in polarized
immune responses, CCL5 can attract both Th2- and Th1-type
cells through binding, respectively, to CCR3 and CCR5
(Sallusto et al., 1997; Bonecchi et al., 1998). In the present
study, only IFN-g-producing Th1-type cells were attracted by
CCL5 in the isotype-treated group, probably because all the
human donors included were non-atopic, and thus there
were no Th2-type cells to recruit.
The couple CCL5/CCR5 has been involved in a number of
diseases such as acquired immuno deficiency syndrome (He
et al., 1997; Blanpain et al., 2002), rheumatoid arthritis
(Suzuki et al., 1999), Crohn’s disease (Oki et al., 2005),
multiple sclerosis (Zang et al., 2000), acute renal allograft
rejection (Panzer et al., 2004), hepatitis C virus infection
(Hellier et al., 2003), Wegener’s granulomatosis (Zhou et al.,
2003), and also asthma (Schuh et al., 2002). Because CCR5
antagonists may have therapeutic potential in such human
diseases, it is of importance to evaluate the part of CCR5 in
the functional effects of CCL5. Studies in mice deficient in
CCR5 so far have shown prolongation of graft survival
(Luckow et al., 2004; Amano et al., 2005) but only limited
defects in cell-mediated immune responses (Field et al.,
2003; Algood and Flynn, 2004; Zhong et al., 2004), which
might be linked to the appearance of compensatory
mechanisms (Chen et al., 2003) that lead to an under-
estimation of the therapeutic potential of receptor antagonists
carriers of the wild-type receptor. To evaluate the effect of
CCR5 neutralization on CCL5-induced leukocyte recruit-
ment, we privileged the use of neutralizing antibody, and
chose the potent anti-human CCR5 inhibitory antibody 2D7,
previously shown to bind to the second extracellular loop of
the receptor (Lee et al., 1999). Humanized SCID mice treated
with anti-CCR5 antibody did not show modifications of
CD45þ leukocyte, CD4þ , and CD8þ T-cell recruitment into
grafts injected with CCL5. In contrast, there was a partial
inhibition of memory T-cell recruitment, showing that CCL5
acts only on a subset of memory T cells through CCR5.
Indeed, memory T cells were still significantly attracted in
vivo by CCL5, suggesting that CCR5 is not the only receptor
able to mediate the recruitment of memory T cells. Anti-
CCR5 treatment did not inhibit CCL5-induced murine
eosinophil recruitment in vivo, although eosinophils do
express CCR5 (Oliveira et al., 2002), and CCL5 has a higher
a b
dc
Figure 5. Immunostaining of cryostat sections of human skin grafts.
Anti-CD68 staining of CCL5-injected skin grafts in SCID mice treated
with (a) IgG2a (Bar¼ 50 mm) or (b) anti-CCR5 (Bar¼ 50mm) antibody.
Anti-IFN-g staining of CCL5-injected skin grafts in SCID mice treated with
(c) IgG2a (Bar¼ 25 mm) or (d) anti-CCR5 (Bar¼25 mm) antibody.
Immunostaining was performed by using the alkaline phosphatase
antialkaline phosphatase technique.
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affinity for CCR5 than for CCR3 in vitro (Blanpain et al.,
2001), and although in vitro chemotaxis assays showed that
the anti-human CCR5 antibody was able to at least partially
inhibit CCL5-induced murine eosinophil recruitment. These
results suggest that CCR5 usage differs in vitro and in vivo,
and that CCR5 is not a major pathway for eosinophil
recruitment by CCL5 in vivo. This is consistent with a
previous study showing that CCR3 is more likely to be the
major pathway of eosinophil recruitment in vivo, at least in
the human allergic reaction (Senechal et al., 2002) where
CCL5 is overexpressed (Ying et al., 1999).
Th1-type cells and monocytes/macrophages express CCR5
(Weber et al., 2000) and CCR1, which both bind CCL5 with
high affinity. Therefore, it is of interest that anti-CCR5
treatment dramatically reduced the recruitment of those cells
by CCL5. These differential results might be explained by a
divergence in CCL5 binding capacity in vivo to the different
receptors. For example, it has been shown that CD26
dipeptidyl peptidase IV can cleave CCL5 at the amino–termi-
nus, which leads to a truncated form of the molecule, this
form showing an altered receptor specificity with reduced
activity towards CCR1 but a conserved activity towards CCR5
(Oravecz et al., 1997). Therefore, although there is a strong in
vitro redundancy of both CCL5 and CCR5 at the cell level,
our study shows that cell selectivity can occur in vivo.
Taken together, these data suggest that in vivo CCL5
selectively uses CCR5 to recruit monocytes/macrophages and
Th1-type cells, into human tissue, and that targeting CCR5
may prove therapeutically beneficial in diseases where the
protagonists are cell types affected by CCR5 blockade, such
as Crohn’s disease (Oki et al., 2005), acquired immuno
deficiency syndrome (Blanpain et al., 2002), multiple
sclerosis (Zang et al., 2000), rheumatoid arthritis (Suzuki
et al., 1999), and transplant rejection.
MATERIALS AND METHODS
Reagents
Anti-human CD45, CD25 (IL-2 receptor chain a), and CD4
antibodies were purchased from BD Biosciences (Pont de Claix,
France). Anti-human CD8, CD68 (macrophages), CD1a (DC
phenotype), CD45RO (memory T-cell phenotype), control IgG,
rabbit anti-mouse Ig, and monoclonal alkaline phosphatase antialka-
line phosphatase antibodies were from Dako (Glostrup, Denmark).
Rabbit antiserum specific for murine major basic protein antibody
was produced as described previously (Filley et al., 1981).
Monoclonal antibody BB1 was used to stain specifically human
basophils (McEuen et al., 1999). Anti-human CCR5 monoclonal
antibody (clone 2D7), IgG2a isotype control (clone G155-178), rat
anti-human IL-4 (MP4-25D2), IL-5 (JES1-39D10), and IL-2 (MQ1-
17H12) were purchased from BD Pharmingen, San Diego, CA.
Mouse anti-human IFN-g (MD2 clone F14) was from HyCult
biotechnology (Uden, The Netherlands). Alkaline phosphatase
activity was developed using Fast Red/naphtol ASMX tablets (Sigma,
St Quentin Fallavier, France). Anti-human antibodies displayed no
cross-reactivity with murine structures, as verified by immunohisto-
chemistry on cryostat sections from biopsies performed at the
border between human and murine tissue. Recombinant human
chemokine CCL5 was purchased from Peprotech (Rocky Hill, NJ)
and reconstituted with sterile phosphate-buffered saline (PBS). CCL5
was endotoxin-free as assessed by a Limulus amebocyte lysate test
(Bio Whittaker, Walkersville, MD).
Human donors
Genotype analysis of CCR5 and CCR5D32 mutation was performed
on a 5 ml blood sample taken before the surgery. Only donors
without mutation were allowed to enter the study. Skin from human
donors was obtained from truncal operation where skin was
discarded. Skin was kept in sterile normal saline with added
penicillin and streptomycin and transplanted onto SCID mice within
2 hours after harvesting. Blood from donors was collected on heparin
6 weeks after surgery. The protocol was approved by the Centre
Hospitalier Re´gional et Universitaire ethical committee (no. 96102).
All donors signed an informed consent form according to the
Declaration of Helsinki Principles.
Animals
Inbred mice with severe combined immunodeficiency (CB-17 SCID
mice) were obtained from breeding pairs originally provided by M.
Lieberman (Stanford University, Stanford, CA) maintained at the
Institut Pasteur de Lille in sterilized isolators. Leaky mice (displaying
spontaneous IgG production after 6 weeks of age) were discarded.
The mice were housed under pathogen-free conditions. Animals
were handled according to the ethical principles of animal
experimentation established by the European Center of Tufts
University.
Skin grafting
Skin grafting was performed as described by Yan et al. (1993). After
anesthesia, 6- to 8-week-old mice were prepared for grafting by
shaving the hair from a 5-cm2 area on each side of the lateral
abdominal region. Two circular graft beds, approximately 1.5 cm
diameter, were prepared by removing shaved murine skin. Full-
thickness human skin grafts of the same size were placed onto
wound beds. The transplants were held in place using 6/0 silk suture
material and covered with an adhesive wound dressing and then
with a standard bandage. Dressing material and sutures were
removed 10 days after transplantation.
Experimental protocol
Six weeks after human skin transplantation, anti-asialo GM1 (1/20
dilution, Wako, Osaka, Japan) was injected intraperitoneally.
Twenty-four hours later, SCID mice were reconstituted intraperito-
neally with 10–15 106 autologous PBMC purified from the donor’s
blood using a Ficoll–Hypaque (Pharmacia, Uppsala, Sweden)
gradient after platelet depletion and resuspended in PBS. PBMCs
were incubated 30 minutes before intraperitoneal reconstitution with
either 100 mg neutralizing anti-human CCR5 antibody (azide-free,
endotoxin level less than 0.01 ng/ml protein) (n¼ 7 mice), or 100mg
irrelevant isotype-matched IgG2a antibody (n¼ 6 mice). In addition,
150mg of the corresponding antibody was injected intraveneously in
each group of mice. CCL5 (4mg in 50 ml diluent solvent) was then
injected intradermally immediately, with 5% Evans blue dye (Sigma)
to mark the site of injection. The contralateral graft of each mouse
was injected with diluent containing an equivalent amount of
BSA and 5% Evans blue dye to serve as control. Mice with sponta-
neously activated grafts as evidenced by leukocyte infiltration in the
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diluent-injected site were discarded. A total of 13 mice were studied,
representing 26 grafts.
Genotype analysis of CCR5 and CCR5D32 mutation by PCR
Because the prevalence of the heterozygous D32 mutation is
10–15% for Europe, and that individuals with this phenotype exhibit
reduced cell surface expression of CCR5 (Berger et al., 1999), we
systematically verified the CCR5 genotype of the cell donors. Three
106 PBMC were resuspended in TRIzol reagent (Life Technologies,
Gaithersburg, MD) and total DNA was extracted according to the
manufacturer’s procedure and yielded 15 mg genomic DNA. The
primers (forward) 50-TCA AAA AGA AGG TCT TCA TTA CAC C-30
and (reverse) 50-AGC CCA GAA GAG AAA ATA AAC AAT C-30
(Eurogentec, Seraing, Belgium) were used to amplify the CCR5 wild-
type and the 32 bp mutation using the following PCR conditions:
100 ng genomic DNA, 5ml of 10 buffer, 200 mM dNTPs, 400 nM of
each primer, and 2.5 U platinium Taq DNA polymerase (Gibco BRL,
Cergy Pontoise, France). Amplification was initiated by a 4-minute
denaturation step at 941C, followed by 35 cycles at 941C for
20 seconds, 581C for 30 seconds, and 721C for 1 minute, followed by
10 minutes extension at 721C using a DNA thermal cycler (Techne,
Cyclogene, Duxford, Cambridge, UK). Amplified PCR products were
separated by gel electrophoresis in 1.5% agarose gel after Gelstar
nucleic acid staining (FMC Bioproducts, Rockland, ME).The CCR5
D32 allele yields a product of 209 bp, clearly distinct from the
wild-type CCR5 at 241 bp.
Immunohistochemistry
Human skin biopsies were performed at the site of injection marked
by Evans blue dye 24 hours after the intradermal injections using a
cylindrical sterile punch and cut into two halves. One-half was
immediately embedded in OCT compound (Labonord, Villeneuve
d’Ascq, France), snap-frozen in isopentane, precooled in liquid
nitrogen, and stored at 801C. Cryostat sections (6 mm) were cut, air-
dried, fixed in a mixture of 60% acetone and 40% methanol, dried,
wrapped in aluminum foil, and stored at 201C for immunohisto-
chemistry. The other half was fixed in 4% paraformaldehyde and
washed in 15% PBS/sucrose before OCT embedment, freezing, and
storage as described above. For all antibodies except antibodies
against IL-4, IL-5, and IL-2, immunohistochemistry was performed
on acetone/methanol fixed sections using a modified alkaline
phosphatase antialkaline phosphatase method as described pre-
viously (Tsicopoulos et al., 1994). Briefly, cryostat sections were
incubated with the primary antibody for 1 hour, washed in Tris-
buffered saline, and successively incubated 30 minutes with rabbit
anti-mouse iG antibody and then alkaline phosphatase antialkaline
phosphatase diluted in 20% normal human ABþ serum. The color
was developed using Fast Red and sections were counterstained with
hematoxylin. Irrelevant primary antibody of the same species was
used as negative control. For IL-4, IL-5, and IL-2, immunohisto-
chemistry was performed on 4% paraformaldehyde fixed sections by
using a modified avidin–biotin complex method, as described
previously (Tsicopoulos et al., 2000). Briefly, cryostat sections were
incubated in 0.3% Triton X-100 for 20 minutes and with PBS
containing 1% hydrogen peroxide. Endogenous biotin was
quenched by using a Vector laboratory kit (Peterborough, UK).
Sections were preincubated with rabbit serum and incubated
overnight with the anti-cytokine antibodies in PBS containing
0.1% saponin (Sigma). Sections were treated with the ABC
Vectastain Elite kit (Vector) and the color developed by using
diaminobenzidine tetrahydrochloride-nickel (Vector). Substitution of
the primary antibody with an irrelevant antibody of the same species
was used as a negative control.
Human T-cell and murine eosinophil chemotaxis assays
Human anti-CD3-/anti-CD28-activated PBMC and a human CD8
T-cell line were resuspended in RPMI medium at a concentration of
106 cells/ml for use in a chemotaxis assay. Chemotaxis was
performed in 24-well transwell chambers (Costar, VWR Internation-
nal, Leuven, Belgium). Cell suspensions (100 ml) were placed in the
upper compartment and 600 ml CCL5 at a concentration of 10 nM in
the bottom compartment. Incubation was performed for 1.5 hours at
371C. Where appropriate, cells were incubated with either
neutralizing anti-hCCR5 antibody (2D7), isotype control, or RPMI
medium as control. Cells that had migrated through the filter were
counted by flow cytometry by counting the events accumulated over
30 seconds.
Murine eosinophils were obtained from IL-5 transgenic mice.
After the killing, spleen eosinophils were resuspended at a
concentration of 106 cells/ml and incubated with medium, control
IgG2a or anti-CCR5 antibody at a final concentration of 10 mg/ml.
Chemotaxis was induced using human CCL5 at 107 M. Eosinophils
that had migrated through the filter were counted under a
microscope at a magnification of 500-fold. Each condition was
performed in triplicate, and at least four fields were counted for each
well. Chemotaxis was distinguished from chemokinesis as described
previously (Fahy et al., 1999). Results were expressed as the mean
number of cells migrating to CCL5 after subtraction of the control
(medium7antibody).
Quantification and statistical analysis
Slides were coded and counted in a blinded manner at  250
magnification using an eyepiece graticule. At least three sections
from each biopsy specimen were cut at different levels and stained
with each antibody. Absolute numbers of positive cells were counted
along the epithelial edge, on a surface of 1 mm wide and 0.4 mm
deep for both chemokine-injected and diluent-control samples.
Results were expressed as the number of positive cells per mm2.
Statistical analysis was performed using Statview 5 software.
Differences within anti-CCR5- and IgG2a-treated groups were first
evaluated for the four subgroups using the Kruskal–Wallis test. When
statistical significance was observed, differences were subsequently
analyzed by using the Wilcoxon test for diluent/CCL5 pairs, and the
unpaired Mann–Whitney test for anti-CCR5- and IgG2a-treated
groups after subtraction of the diluent value from the chemokine
value. Only P-valuesp0.05 were considered significant.
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